ARQT News and Press, Arcutis Biotherapeutics Inc. From 09/18/22

Summary Shares of dermatology biopharma Arcutis Biotherapeutics, Inc. fell 16% the day after receiving its first FDA approval for ZORYVE (roflumilast) in the treatment of plaque psoriasis. The market seemed to be anticipating a secondary offering, which was executed three days lat...

The following slide deck was published by Arcutis Biotherapeutics, Inc. in conjunction with this event. For further details see: Arcutis Biotherapeutics (ARQT) Investor Presentation - Slideshow

Summary Zoryve (roflumilast cream) was approved by the FDA to treat psoriasis on August 1, 2022. The phase 3 STRATUM trial met the endpoint and an NDA will be submitted to FDA for roflumilast foam to be approved for the treatment of seborrheic dermatitis. Roflumilast is potent...

Study met its primary endpoint with 80% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared to 59% of patients treated with vehicle (P<0.0001) More than 60% of patients treated with roflumilast foam achieved an itch response ...

Arcutis Biotherapeutics ( NASDAQ: ARQT ) to acquire Ducentis BioTherapeutics Ltd., a preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases. Per the terms, Arcutis will acquire the outstanding shares of Ducent...

LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million PR Newswire First exit for LifeArc Ventures, the largest investor in Ducentis, recognising the transformational potential of its science Ducentis lead pre-...

Arcutis Biotherapeutics ( NASDAQ: ARQT ) on Wednesday said it would acquire Ducentis BioTherapeutics, a privately-held, preclinical-stage biotech developing therapies for inflammation autoimmune diseases. As per the share purchase agreement, Arcutis ( ARQT ) will acqui...

Leverages Arcutis’ deep dermatology expertise and broad biologics experience to accelerate Ducentis’ lead compound, DS-234, in atopic dermatitis Lead indication, atopic dermatitis, is a rapidly growing, significantly underserved market with large unmet need Checkpo...

WESTLAKE VILLAGE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that four abstracts for Arcutis’ topical roflumilas...

WESTLAKE VILLAGE, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that Neha Krishnamohan has been appointed to the Arcutis B...